India | UK | US

Pfizer gains rights to Medivation Alzheimer's drug

NEW YORK (Reuters) - Pfizer Inc <PFE.N> is acquiring rights to a promising experimental drug for Alzheimer's disease from Medivation Inc <MDVN.O> for as much as $725 million, sending Medivation shares up nearly 31 percent.
Posted : Wed, 03 Sep 2008 12:51:50 GMT
By : Reuters
Category : US (Business)
News Alerts by Email ( click here )
US Business News | Home
NEW YORK (Reuters) - Pfizer Inc is acquiring rights to a promising experimental drug for Alzheimer's disease from Medivation Inc for as much as $725 million, sending Medivation shares up nearly 31 percent.

Pfizer, which is seeking to boost its pipeline of experimental drugs, will pay an initial $225 million for rights to the medicine, Dimebon, which is also being developed for Huntington's disease, the companies said on Wednesday.

The world's largest drug maker will pay San Francisco-based Medivation up to $500 million more should Dimebon reach various development and regulatory goals, plus additional undisclosed commercial milestone payments.

Results for Dimebon were presented at a prominent Alzheimer's conference in July, when the drug showed it kept symptoms of the brain-wasting disease at bay for 18 months.

No cure exists for Alzheimer's disease, the most common form of dementia, and current drugs just delay symptoms somewhat.

Pfizer will collaborate on the Phase 3 program in Alzheimer's disease, Huntington's disease development, and regulatory filings in the United States.

The New York-based company will assume 60 percent of U.S. development and commercialization expenses, and receive 60 percent of U.S. profits. Medivation will co-promote Dimebon to specialty physicians in the United States, should the drug reach the market.

Pfizer will have responsibility for the drug outside the United States and will pay Medivation royalties on sales.

Medivation started enrolling patients in June for a 525-patient Phase 3 trial for Alzheimer's disease.

In July, Medivation said a mid-stage trial showed Dimebon significantly improved cognitive function in patients with Huntington's disease, a condition in which the degeneration of brain cells causes uncontrolled movement and loss of intellectual function.

Medivation shares rose to $34 in premarket trading from Tuesday's close of $26.03. Pfizer rose 8 cents to $19.25.

(Reporting by Lewis Krauskopf; Editing by Steve Orlofsky and Lisa Von Ahn)


(c) Reuters 2008. All rights reserved. Republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters and the Reuters sphere logo are registered trademarks and trademarks of the Reuters group of companies around the world.

Share/Save/Bookmark

Article : Pfizer gains rights to Medivation Alzheimer's drug
Print this article
Email this article

Stay Updated
News gadget on your Google homepage
Subscribe to a news feed in Google Reader


Related News

Five more US bank failures bring total for 2009 to 120
New York - Bank failures in the United States have risen to 120 this year as five more regional institutions were added to the list, the US agency that guarantees the safety of bank deposits said. United Commercial Bank in San Francisco with assets o...

US stocks climb slightly despite double-digit jobless rate
New York - US stocks posted mild gains Friday to end the week as investors shrugged off government figures that put the unemployment rate above 10 per cent. The Labour Department said the jobless rate hit 10.2 per cent in the month of October, the hi...

US joblessness hits 10.2 per cent, highest in 26 years - Summary
Washington - The US unemployment rate surged to 10.2 per cent in October, the highest in 26 years as another 190,000 people lost their jobs, the Labour Department reported Friday. The figure comes after a 9.8-per-cent jobless rate in September and wa...

US joblessness jumps to 10.2 per cent, highest since 1983 - Update
Washington - The US unemployment rate surged to 10.2 per cent in October, the highest in 26 years, as another 190,000 people lost their jobs during the month, the US reported Friday. The figure reported by US Labour Department came after the 9.8 per ...

US jobless rate jumps to 10.2 per cent
Washington - The US unemployment rate surged to 10.2 per cent in October as another 190,000 people lost their jobs, according to US Labour Department figures released Friday. The jobless rate stood at 9.8 per cent in September. Unemployment had been ...

Bulls stop James, edge Cavs - Summary
Los Angeles - The King couldn't deliver in the clutch. Luol Deng and Joakim Noah combined to deny LeBron James a potential game-winning drive in the final seconds as and the visiting Chicago Bulls snapped the Cleveland Cavaliers' three-game winning...

Mortgage lender Fannie Mae posts nearly 19-billion-dollar loss
Washington - US mortgage lender Fannie Mae said Thursday that it would seek 15 billion dollars in federal aid, after posting its ninth consecutive quarterly loss. Fannie Mae reported a net loss of 18.9 billion dollars in the third quarter of 2009, co...

Have your Say
Name
Email
Subject
Your Comment

Enter Verification code
 
  

 

 

More US (Business) News click here
Follow The Earth Times
Subscribe to RSS Follow Earth Times on TwitterNews by email
Share/Save/Bookmark

 
 



 
Subscribe to free Earthtimes
News Alerts by Email Click here
For RSS Feeds Click here
or Create your own RSS

Add to Google Toolbar
Breaking News
Press Releases

 


The Earth Times
News Category

© 2009 www.earthtimes.org, The Earth Times, All Rights Reserved | Privacy Policy
Earth Times accept no responsibility or liability either directly or indirectly for views or opinions expressed in articles or comments.